Prestige Biologics Co. Ltd.
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for… Read more
Prestige Biologics Co. Ltd. (334970) - Total Liabilities
Latest total liabilities as of September 2025: ₩147.13 Billion KRW
Based on the latest financial reports, Prestige Biologics Co. Ltd. (334970) has total liabilities worth ₩147.13 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Prestige Biologics Co. Ltd. - Total Liabilities Trend (2018–2024)
This chart illustrates how Prestige Biologics Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Prestige Biologics Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Prestige Biologics Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Melcor Real Estate Investment Trust
TO:MR-UN
|
Canada | CA$494.70 Million |
|
Daesung Hi-Tech Co. Ltd.
KQ:129920
|
Korea | ₩130.51 Billion |
|
Alvotech Warrant
NASDAQ:ALVOW
|
USA | $1.59 Billion |
|
MAGELLANIC CLOUD LTD
NSE:MCLOUD
|
India | ₹4.53 Billion |
|
Enertork Ltd
KQ:019990
|
Korea | ₩8.34 Billion |
|
Bound and Beyond PCL
BK:BEYOND
|
Thailand | ฿6.75 Billion |
|
Ringmetall SE
XETRA:HP3A
|
Germany | €94.68 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Prestige Biologics Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prestige Biologics Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prestige Biologics Co. Ltd. (2018–2024)
The table below shows the annual total liabilities of Prestige Biologics Co. Ltd. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩135.08 Billion | -37.96% |
| 2023-12-31 | ₩217.73 Billion | +55.00% |
| 2022-12-31 | ₩140.47 Billion | +40.56% |
| 2021-12-31 | ₩99.94 Billion | +93.56% |
| 2020-12-31 | ₩51.63 Billion | +19.36% |
| 2019-12-31 | ₩43.25 Billion | -40.21% |
| 2018-12-31 | ₩72.35 Billion | -- |